by Lori Solomon HealthDay Reporter The U.S. Food and Drug Administration has approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with HIV-1 whose HIV infection cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations. Sunlenca is the first FDA-approved capsid inhibitor for treating HIV-1....
